dc.rights.license | OTH | en_US |
dc.contributor.author | Gamelin, François-Xavier | |
dc.contributor.author | Cuvelier, Grégory | |
dc.contributor.author | Mendes, Antoine | |
dc.contributor.author | Aucouturier, Julien | |
dc.contributor.author | Berthoin, Serge | |
dc.contributor.author | Di Marzo, Vincenzo | |
dc.contributor.author | Heyman, Elsa | |
dc.date.accessioned | 2021-04-23T12:12:32Z | |
dc.date.available | 2021-04-23T12:12:32Z | |
dc.date.issued | 2020-03-20 | |
dc.identifier.issn | 1043-6618 | en_US |
dc.identifier.uri | https://luck.synhera.be/handle/123456789/906 | |
dc.identifier.doi | https://doi.org/10.1016/j.phrs.2020.104764 | en_US |
dc.description.abstract | In the sports domain, cannabis is prohibited by the World Anti-Doping Agency (WADA) across all sports in
competition since 2004. The few studies on physical exercise and cannabis focused on the main compound i.e.
Δ9-tetrahydrocannabinol. Cannabidiol (CBD) is another well-known phytocannabinoid present in dried or heated
preparations of cannabis. Unlike Δ9-tetrahydrocannabinol, CBD is non-intoxicating but exhibits pharmacological
properties that are interesting for medical use. The worldwide regulatory status of CBD is complex and
this compound is still a controlled substance in many countries. Interestingly, however, the World Anti-Doping
Agency removed CBD from the list of prohibited substances – in or out of competition - since 2018. This recent
decision by the WADA leaves the door open for CBD use by athletes. In the present opinion article we wish to
expose the different CBD properties discovered in preclinical studies that could be further tested in the sport
domain to ascertain its utility. Preclinical studies suggest that CBD could be useful to athletes due to its antiinflammatory,
analgesic, anxiolytic, neuroprotective properties and its influence on the sleep-wake cycle.
Unfortunately, almost no clinical data are available on CBD in the context of exercise, which makes its use in this
context still premature. | en_US |
dc.description.sponsorship | None | en_US |
dc.description.tableofcontents | 1. Introduction
2. Overview of CBD
3. Anti-inflammatory and analgesic effects
4. Anxiolytic effects
5. Neuroprotective effects
6. Sleep disturbances
7. Limits
8. Conclusions | en_US |
dc.language.iso | EN | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Pharmacological Research | en_US |
dc.rights.uri | https://www.elsevier.com/legal/elsevier-website-terms-and-conditions | en_US |
dc.subject | Anxiolytic | en_US |
dc.subject | Cannabidiol | en_US |
dc.subject | Cannabis | en_US |
dc.subject | Doping | en_US |
dc.subject | Neuroprotective | en_US |
dc.subject | Sleep-wake cycle | en_US |
dc.subject.fr | Anxiolytiques | en_US |
dc.subject.fr | Dopage | en_US |
dc.subject.fr | Propriétés neuroprotectrices | en_US |
dc.subject.fr | Cycle éveil-sommeil | en_US |
dc.title | Cannabidiol in sport : Ergogenic or else ? | en_US |
dc.type | Article scientifique | en_US |
synhera.classification | Sciences de la santé humaine>>Orthopédie, rééducation & médecine sportive | en_US |
synhera.institution | HE Condorcet | en_US |
synhera.otherinstitution | Institute of biomolecular chemistry, Pozzuoli | en_US |
synhera.otherinstitution | Université d'Artois, Lille | en_US |
synhera.otherinstitution | Université de Laval, Quebec | en_US |
synhera.cost.total | 0 | en_US |
synhera.cost.apc | 0 | en_US |
synhera.cost.comp | 0 | en_US |
synhera.cost.acccomp | 0 | en_US |
dc.description.version | Oui | en_US |
dc.rights.holder | Elsevier | en_US |